Multiple Technology Appraisals (MTAs)
MTAs evaluate multiple drugs in the same indication. In MTAs, SCHARR-TAG systematically reviews, synthesises the clinical evidence, and constructs its own mathematical model providing estimates of cost-effectiveness to the NICE appraisal committee.
Off
2023 | 2021 | 2020 | 2019 | 2017 | 2016 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000
2023
.
2021
.
2020
.
2019
.
2017
.
2016
.
.
.
2014
.
2013
.
2012
.
2011
.
2010
.
2009
.
.
.
.
2008
.
.
2007
.
.
.
.
.
2006
.
.
.
2005
.
.
2004
.
.
.
.
.
.
.
2003
.
.
.
.
.
.
.
.
2002
.
.
.
2001
.
.
.
2000
.